Document is current
Any future updates will be listed below
-
Authors
Wan, Ping https://orcid.org/0000-0003-2884-6270
Tang, Siyuan
Lin, Dongni https://orcid.org/0000-0002-2469-804X
Lu, Yuming https://orcid.org/0000-0002-0183-5574
Long, Mei
Xiao, Ling
Jiang, Yanhong
Liao, Jiaoyang https://orcid.org/0000-0002-0443-563X
Ma, Xiaoying
Liu, Ying
Yu, Wensu
Ott, Michael https://orcid.org/0000-0002-1245-358X
Wang, Zi Jun https://orcid.org/0000-0001-8977-4317
Wu, Yuxuan https://orcid.org/0000-0002-9155-9883
Yang, Taihua https://orcid.org/0000-0001-6767-5027
Xia, Qiang https://orcid.org/0000-0001-9482-6951
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 2 February 2026
First Online: 3 March 2026
Competing interests
: L.X., X.M., Y. Liu and W.Y. are employees of YolTech Therapeutics. M.O is a member of the advisory board for YolTech Therapeutics. Y. Lu, Z.J.W. and Y.W. are cofounders of YolTech Therapeutics. YOLT-101, the investigational product used in this study, is developed by YolTech Therapeutics. These relationships did not influence the study design, data collection, analysis or interpretation. The other authors declare no competing interests.
